Empirical Financial Services LLC d.b.a. Empirical Wealth Management Invests $530,000 in Smith & Nephew SNATS, Inc. $SNN

Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 14,601 shares of the medical equipment provider’s stock, valued at approximately $530,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its position in Smith & Nephew SNATS by 11.7% during the third quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 401 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Smith & Nephew SNATS by 5.0% during the 3rd quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock valued at $323,000 after purchasing an additional 423 shares during the last quarter. Inspire Investing LLC increased its position in shares of Smith & Nephew SNATS by 7.1% during the 3rd quarter. Inspire Investing LLC now owns 7,789 shares of the medical equipment provider’s stock valued at $283,000 after purchasing an additional 516 shares during the last quarter. Cary Street Partners Financial LLC raised its holdings in shares of Smith & Nephew SNATS by 3.8% during the 2nd quarter. Cary Street Partners Financial LLC now owns 20,005 shares of the medical equipment provider’s stock valued at $613,000 after buying an additional 725 shares in the last quarter. Finally, MAI Capital Management lifted its position in Smith & Nephew SNATS by 24.0% in the 2nd quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock worth $134,000 after buying an additional 846 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNN has been the topic of a number of recent research reports. Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Wall Street Zen lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group decreased their target price on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday, November 11th. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Finally, Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $35.75.

Smith & Nephew SNATS Price Performance

NYSE:SNN opened at $36.17 on Tuesday. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. The company has a fifty day moving average of $33.85 and a 200 day moving average of $34.94. Smith & Nephew SNATS, Inc. has a 52 week low of $23.91 and a 52 week high of $38.79.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.